CASTLE ROCK, CO--(Marketwire - April 07, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has entered a long-term exclusive license and commercialization agreement with Novartis Animal Health, Inc. for the development and launch of AspenBio's novel recombinant single-chain bovine products, BoviPure LH™ and BoviPure FSH™.
